Printer Friendly

EMBREX REPORTS FOURTH QUARTER AND YEAR-END RESULTS

 EMBREX REPORTS FOURTH QUARTER AND YEAR-END RESULTS
 RESEARCH TRIANGLE PARK, N.C., March 27 /PRNewswire/ -- Embrex Inc.


(NASDAQ: EMBX, EMBXW) today reported financial results for the fourth quarter and year ended Dec. 31, 1991.
 For the fourth quarter of 1991, Embrex reported operating expenses of $1,494,207 and a net loss of $1,454,291 (56 cents per share) compared with operating expenses of $1,010,952 and a net loss of $1,031,290 (63 cents per share) for the fourth quarter of last year.
 For the year 1991, Embrex reported revenues of $96,020, operating expenses of $4,252,818 and a net loss of $4,739,612 ($2.26 per share). For 1990, the comparable figures were revenues of $49,460, operating expenses of $3,771,445, and a net loss of $3,694,000 ($2.22 per share).
 "The financial results for the quarter and year were in line with our expectations," said Randall L. Marcuson, Embrex operating president and chief executive officer. "The increase in fourth quarter expenses was a result of increased research and product development spending and some increase in administrative expenses associated with becoming a publicly traded company."
 During the fourth quarter, Embrex closed an initial public offering which netted the company $16.7 million. On Dec. 31, 1991, Embrex had total current assets of $15.6 million, including $15.5 million in cash and cash equivalents.
 Embrex Inc. develops and has recently begun marketing bioscience and bioengineering-based products to increase the productivity and profitability of the poultry industry.
 EMBREX INC.
 (A Development Stage Company)
 Selected Statement of Operations Data
 Periods ended Three Months Twelve Months
 Dec. 31 1991 1990 1991 1990
 Total revenues -- $ 20,796 $ 96,020 $ 49,460
 Total operating
 expenses $ 1,494,207 1,010,952 4,252,818 3,771,445
 Net loss $(1,454,291) $(1,031,290) $(4,739,612) $(3,694,000)
 Net loss per shr.
 of common stock $(0.56) $(0.63) $(2.26) $(2.22)
 Wtd. aver. shares
 of common stock
 outstanding 1,454,291 1,031,290 2,096,325 1,661,610
 -0- 3/27/92
 /CONTACT: John A. Hagan of Embrex, 919-941-5185, or Douglas Johnson of GreenTree Communications, 800-428-8796, for Embrex/
 (EMBX) CO: Embrex Inc. ST: North Carolina IN: FOD SU: ERN


GK-TS -- NY008 -- 2236 03/27/92 08:08 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 27, 1992
Words:392
Previous Article:THE GREENBRIER HOLDS WELCOMING CEREMONY COMMEMORATING INAUGURAL FLIGHT
Next Article:MANAGEMENT TECHNOLOGIES ADDS THREE KEY EXECUTIVES
Topics:


Related Articles
EMBREX REPORTS THIRD QUARTER AND NINE MONTH RESULTS
EMBREX'S NEW INOVOJECT SYSTEM COMPLETES SECOND PERFORMANCE SERIES
EMBREX REPORTS FIRST-QUARTER RESULTS
EMBREX, INC. REPORTS RECORD FOURTH QUARTER AND FULL YEAR REVENUES
In Ovo Infectious Bursal Disease Vaccine Approved By USDA
Multi-Hatchery Trials of 20 Million Broilers Show Bursaplex Improves Key Production Parameters
Embrex Names Joseph O'Dowd Director of Latin America
Embrex Second-Quarter Net Income Up 45% Due To Continued Revenue Growth
Embrex's In Ovo Vaccine, Bursaplex(TM), Receives Regulatory Approval From Thailand

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters